As is often the case with cancer treatments, many patients are able to benefit from therapy for a time. Tumor activity decreases, scans show improvement, and patient lifespans are prolonged for some ...

Ovarian cancer treatment faces challenges with high relapse and drug resistance rates, despite initial chemotherapy effectiveness. Cytokines like IL-6 and IL-11 are associated with complex tumor ...

Preclinical research showed that ascites may actively protect metastatic ovarian cancer against ferroptosis and help drive ...

Ovarian cancer is the deadliest gynecologic malignancy globally and is increasing in incidence and mortality with currently more than 300,000 new cases and 200,000 deaths annually, according to data ...

A fluid that women with advanced ovarian cancer know all too well - ascites, the buildup of liquid in the belly - may be doing more than causing discomfort.

NEW YORK — Scientists have identified a potentially game-changing treatment approach for ovarian cancer, one of the deadliest forms of the disease that kills roughly 12,740 American women each year.

Anixa Biosciences, Inc. ANIX on Monday provided an update on patient outcomes observed in its ongoing Phase 1 ovarian cancer CAR-T clinical trial, following regulatory approval of a protocol amendment ...

A new drug is showing promise in tackling treatment-resistant ovarian cancer. Relacorilant, the drug tested in a phase 3 ROSELLA trial with Corcept Therapeutics in California, was found to improve ...

Ovarian cancer research is entering a pivotal era characterized by increasing complexity for large, global studies.

Ovarian cancer is the sixth leading cause of cancer-related death among women in the United States. It is largely asymptomatic in early‑stage disease, leading to diagnosis at advanced stages for most ...

A panelist discusses how antibody-drug conjugates like mirvetuximab should be sequenced in platinum-resistant ovarian cancer, recommending it as first-line therapy for folate receptor alpha–high ...